Navigation Links
Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
Date:1/5/2009

sing metabolism and allowing the body to continue losing weight by offsetting its natural tendency to fight back and slow down the weight loss process. Contrave is being studied in four Phase 3 trials, all of which have completed enrollment. We expect to provide results from all four Phase 3 trials by mid-2009. We remain on target to file a New Drug Application (NDA) with the FDA in late 2009.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed," "projects" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding enrollment, timing, execution and completion of clinical trials of Contrave, the timing of an NDA submission with the FDA for Contrave, the efficacy and safety of Contrave, the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave, and the potential issuance of patents and the scope and duration of p
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... -- Senior Vice President, General Manager for ... business acumen Elsevier , a world-leading ... services, congratulates Diane Bartoli , Senior Vice President ... Clinical Solutions, for being recognized in the 13 th ... of Profiles in Diversity Journal ® . ...
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... November 22, 2014 The “Chiral ... Preparative), by Material (Metal, Glass, Plastic), by Application ... SFC] - Forecast to 2018” analyses and studies ... in North America, Europe, Asia, and Rest of ... and 15 figures spread through 135 pages and ...
(Date:11/21/2014)... , Todd Martensen ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial ... en marcha para comenzar de forma rápida la comercialización de ... aprobación en Europa   , KLOX ... los siguientes nombramientos: Todd Martensen ha ...
Breaking Biology Technology:Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5
... SHENYANG, China, May 3, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio ... "the Company"), a leading China-based biotechnology company focused ... today announced that it will release its first ... stock market  closes on Wednesday, May 11, 2011 ...
... 3, 2011 At this year,s American Academy of AntiAging ... named the leading factors in premature aging and disease. AGEs ... result of sugar that attaches to a protein or lipid ... AGEs are completely irreversible—and cause accelerated damage to the tissues ...
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a ... diseases, announced today that after scientific review, the ongoing ... for multiple sclerosis (MS) has received an additional $1,594,553 ... Institute of Neurological Disorders and Stroke (NIH/NINDS). The clinical ...
Cached Biology Technology:3SBio Inc. Schedules Unaudited First Quarter 2011 Results 2At This Year's American Academy of AntiAging (A4M) Conference, Glycation and AGEs (Advanced Glycation End Products) Were Named the Leading Factors in Premature Aging and Disease 2Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 2Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 3Adeona's Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant 4
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... have found a way to project future habitat ... for threatened biodiversity. Associate Professor Grant Wardell-Johnson ... Institute for Biodiversity and Climate, along with lead ... now at Wageningen University in the Netherlands, developed ...
... on undersea vehicles that have fish-like sensations, advanced ship ... of Naval Research (ONR) on Dec. 23 learned they ... and engineers. The researchers have been selected for ... and will be honored at a ceremony at the ...
... in a quest to correct a faulty chromosome through cellular ... used stem cells to correct a defective "ring chromosome" with ... chromosome abnormalities that give rise to birth defects, mental disabilities ... be possible to use this approach to take cells from ...
Cached Biology News:Safe havens revealed for biodiversity in a changed climate 2White House lauds ONR-funded researchers for early success 2Nature study discovers chromosome therapy to correct a severe chromosome defect 2Nature study discovers chromosome therapy to correct a severe chromosome defect 3
... isoprostanes produced from arachidonic acid during lipid peroxidation. ... rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced platelet ... µM, respectively. When infused into the renal artery ... mg/kg/min, 8-iso PGE2 decreases the GFR and renal ...
... centrifuge offers both high-speed and high-volume ... of rotor options, making it ideal for ... Maximum Versatility , High-speed (up to ... or high-volume (4 x 250mL) swinging bucket ...
...
... submarine gel systems used gasketed gel trays. Turn the ... tank. Turn it back and run the gel - ... Turn & Cast tray is UV transparent. Each tray ... the tray and one in the center. This allows ...
Biology Products: